|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.10.25 - 21:42
|
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera.
Pfizer alleges that the Novo Nordisk offer cannot qualify as a “Superior Company Proposal” under the terms of the merger agreement, including because, relative to the Pfizer deal, the Novo Nordisk transaction is not reasonably likely to be completed on the terms proposed in light of the significant regulatory risk of the proposal. By contrast, today the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer's pending acquisition of Metsera. All regulatory approvals in respect of P...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.10.25 - 10:42
|
Novo Nordisk Buy (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Novo Nordisk auf "Buy" mit einem Kursziel von 600 dänischen Kronen belassen. Dass der Pharmakonzern mit einer Offerte für die US-Biotechfirma Metsera diese dem US-Rivalen Pfizer wegschnappen wolle, ......
|
|
|
31.10.25 - 08:09
|
Novo Nordisk Outperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Novo Nordisk mit einem Kursziel von 540 dänischen Kronen auf "Outperform" belassen. Metsera würde gut zu den Dänen passen und ihr Ergebnis kaum belasten, schrieb ......
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
